Molecule Details
InChIKeyKXBDTLQSDKGAEB-UHFFFAOYSA-N
Compound NameSpebrutinib
Canonical SMILESC=CC(=O)Nc1cccc(Nc2nc(Nc3ccc(OCCOC)cc3)ncc2F)c1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)8
Pfam Stratification Homologous
Avg pChEMBL7.51
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB11764
Drug NameSpebrutinib
CAS Number1202757-89-8
Groups investigational
ATC Codes nan
DescriptionSpebrutinib has been used in trials studying the treatment of Rheumatoid Arthritis, Lymphoma, Large B-Cell, Diffuse, and Leukemia Lymphocytic Chronic B-Cell.

Categories: Acids, Acyclic Acrylates Amides Enzyme Inhibitors Protein Kinase Inhibitors
Cross-references: CHEMBL3301625 ChemSpider: 29361342 PubChem:59174488 PubChem:347828118 ZINC: ZINC000072319585
Target Activities (8)
Target Gene Organism Category Pfam pChEMBL Type Source
P51813 BMX Homo sapiens Human PF00779 PF00169 PF07714 PF00017 8.5 IC50 ChEMBL;BindingDB
P42680 TEC Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 8.2 IC50 ChEMBL;BindingDB
Q06187 BTK Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 8.2 IC50 ChEMBL;BindingDB
P42681 TXK Homo sapiens Human PF07714 PF00017 PF00018 7.7 IC50 ChEMBL;BindingDB
P52333 JAK3 Homo sapiens Human PF18379 PF18377 PF17887 PF07714 PF21990 7.6 IC50 ChEMBL;BindingDB
Q08881 ITK Homo sapiens Human PF00779 PF00169 PF07714 PF00017 PF00018 7.3 IC50 ChEMBL;BindingDB
P00533 EGFR Homo sapiens Human PF00757 PF14843 PF07714 PF01030 PF21314 6.4 IC50 ChEMBL;BindingDB
O60674 JAK2 Homo sapiens Human PF18379 PF18377 PF17887 PF07714 PF21990 6.3 IC50 ChEMBL;BindingDB
DrugBank Target Actions (1)
Target Gene Target Name Action Type
Q06187 BTK Tyrosine-protein kinase BTK inhibitor targets